UNSPSC 51111646: Nelarabine

This classification denotes a purine antagonist with the molecular formula C11H15N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60158CV180, chemically known as 9h-purin-2-amine, 9beta-d-arabinofuranosyl-6-methyl- but generally known as nelarabine, which bears US NIH Compound Identifier 151121. European Medicines Agency schedules Nelarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09188MIG.

World Health Organization schedules nelarabine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, NELARABINE remains the US FDA Preferred Term for this commodity. Nelarabine bears US NLM identifiers UMLS ID C0907349 and NCI Concept Code C1704. SMILES: COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N..

UNSPSC 51111646 Nelarabine, a Commodity code, names a specific chemotherapy drug used in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoma. State and local governments procure nelarabine primarily through their health and human services departments, Medicaid programs, and public hospital systems to support cancer treatment protocols for eligible patients. The drug is a purine nucleoside analog administered intravenously and is typically sourced as a pharmaceutical supply rather than as a service engagement. Procurement bodies acquiring this pharmaceutical span state departments of health, county hospital systems, city-operated medical centers, and regional cancer care consortia that serve public and Medicaid beneficiaries.

The source provided contains no recent state and local contract opportunities or solicitation records under UNSPSC 51111646. Without access to posted RFP, RFQ, IFB, or ITB notices naming this code, geographic concentration and current market activity cannot be characterized from recent purchasing data. Nelarabine procurement typically occurs through standing pharmaceutical supply contracts, group purchasing organization (GPO) agreements, or specialized oncology drug distribution channels rather than through individual competitive solicitations; as a result, this code may see limited posting of discrete opportunities in general state and local procurement databases.